Remote ischaemic conditioning: defining critical criteria for success-report from the 11th Hatter Cardiovascular Workshop
Por:
Bell, RM, Basalay, M, Botker, HE, Kalkhoran, SB, Carr, RD, Cunningham, J, Davidson, SM, England, TJ, Giesz, S, Ghosh, AK, Golforoush, P, Gourine, AV, Hausenloy, DJ, Heusch, G, Ibanez, B, Kleinbongard, P, Lecour, S, Lukhna, K, Ntsekhe, M, Ovize, M, Salama, AD, Vilahur, G, Walker, JM, Yellon, DM
Publicada:
1 dic 2022
Resumen:
The Hatter Cardiovascular Institute biennial workshop, originally scheduled for April 2020 but postponed for 2 years due to the Covid pandemic, was organised to debate and discuss the future of Remote Ischaemic Conditioning (RIC). This evolved from the large multicentre CONDI-2-ERIC-PPCI outcome study which demonstrated no additional benefit when using RIC in the setting of ST-elevation myocardial infarction (STEMI). The workshop discussed how conditioning has led to a significant and fundamental understanding of the mechanisms preventing cell death following ischaemia and reperfusion, and the key target cyto-protective pathways recruited by protective interventions, such as RIC. However, the obvious need to translate this protection to the clinical setting has not materialised largely due to the disconnect between preclinical and clinical studies. Discussion points included how to adapt preclinical animal studies to mirror the patient presenting with an acute myocardial infarction, as well as how to refine patient selection in clinical studies to account for co-morbidities and ongoing therapy. These latter scenarios can modify cytoprotective signalling and need to be taken into account to allow for a more robust outcome when powered appropriately. The workshop also discussed the potential for RIC in other disease settings including ischaemic stroke, cardio-oncology and COVID-19. The workshop, therefore, put forward specific classifications which could help identify so-called responders vs. non-responders in both the preclinical and clinical settings.
Filiaciones:
Bell, RM:
UCL, Hatter Cardiovasc Inst, 67 Chenies Mews, London WC1E 6HX, England
Botker, HE:
UCL, Hatter Cardiovasc Inst, 67 Chenies Mews, London WC1E 6HX, England
Aarhus Univ Hosp, Aarhus, Denmark
Aarhus Univ, Aarhus, Denmark
Kalkhoran, SB:
UCL, Hatter Cardiovasc Inst, 67 Chenies Mews, London WC1E 6HX, England
Cunningham, J:
Royal Free Hosp, London, England
Davidson, SM:
UCL, Hatter Cardiovasc Inst, 67 Chenies Mews, London WC1E 6HX, England
England, TJ:
Univ Nottingham, Sch Med, Div Mental Hlth & Clin Neurosci, Stroke, Nottingham, England
Giesz, S:
UCL, Hatter Cardiovasc Inst, 67 Chenies Mews, London WC1E 6HX, England
Ghosh, AK:
UCL, Hatter Cardiovasc Inst, 67 Chenies Mews, London WC1E 6HX, England
Gourine, AV:
UCL, Ctr Cardiovasc & Metab Neurosci, Neurosci Physiol & Pharmacol, London, England
Hausenloy, DJ:
UCL, Hatter Cardiovasc Inst, 67 Chenies Mews, London WC1E 6HX, England
Duke NUS, CVMD, Singapore, Singapore
Natl Heart Res Inst Singapore, Natl Heart Ctr, Singapore, Singapore
Asia Univ, Coll Med & Hlth Sci, Cardiovasc Res Ctr, Taichung, Taiwan
Heusch, G:
Univ Duisburg Essen, Inst Pathophysiol, West German Heart & Vasc Ctr, Duisburg, Germany
Ibanez, B:
IIS Fdn Jimenez Diaz Univ Hosp, Ctr Nacl Invest Cardiovasc CNIC, Madrid, Spain
CiberCV, Madrid, Spain
CIBER Enfermedades Cardiovasc CIBERCV, Madrid, Spain
IIS Fdn Jimenez Diaz Hosp, Madrid, Spain
Lecour, S:
Univ Cape Town, Cape Town, South Africa
Lukhna, K:
Univ Cape Town, Cape Town, South Africa
Ntsekhe, M:
Univ Cape Town, Cape Town, South Africa
Ovize, M:
Univ Lyon, Grp Hosp Est, CarMeN Lab, INSERM U1060, F-69500 Bron, France
Vilahur, G:
CIBERCV, Inst Recerca Hosp Santa Creu Sant Pau, Barcelona, Spain
Walker, JM:
UCL, Hatter Cardiovasc Inst, 67 Chenies Mews, London WC1E 6HX, England
Yellon, DM:
UCL, Hatter Cardiovasc Inst, 67 Chenies Mews, London WC1E 6HX, England
hybrid, Green Published, All Open Access, Hybrid Gold, Green
|